All In Biotech

NDA 022568 · Eisai INC

Aricept

Donepezil Hydrochloride · Oral

Last checked: Nov 20, 2026Latest source record: Dec 18, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2010

Jul 23, 2010

Approved uses

1

Original approval plus efficacy supplements

Registered trials

332

55 Phase 3, 12 recruiting

FAERS reports

19,997

14,679 serious, 3,033 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 30, 2021.

ARICEPT is indicated for the treatment of dementia of the Alzheimer’s type. Efficacy has been demonstrated in patients with mild, moderate, and severe Alzheimer’s disease. ARICEPT is an acetylcholinesterase inhibitor indicated for the treatment of dementia of the Alzheimer’s type. Efficacy has been demonstrated in patients with mild, moderate, and severe Alzheimer’s Disease ( 1 )

Mechanism: Current theories on the pathogenesis of the cognitive signs and symptoms of Alzheimer’s disease attribute some of them to a deficiency of cholinergic neurotransmission. Donepezil hydrochloride is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by acetylcholinesterase. There is no evidence that donepezil alters the course of the underlying dementing process.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ARICEPT · DONEPEZIL HYDROCHLORIDE 23MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Donepezil" as an intervention, any sponsor and status, largest first.

All 332 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fall1,630
  • confusional state1,125
  • dizziness1,008
  • death967
  • nausea958
  • diarrhoea943
  • fatigue934
  • asthenia847
  • drug ineffective804
  • hallucination779
  • somnolence761
  • vomiting697

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,108
2005793
2006806
2007578
2008692
2009710
2010948
2011952
2012956
2013748
2014853
20151,211
20161,076
20171,098
2018920
2019816
2020706
2021661
2022888
2023864
2024916
2025957
2026739

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Aricept (Donepezil HCl)

2024 spending

$1.2M

Beneficiaries

368

1,403 claims

Per beneficiary

$3,216

$15.67 per unit

View as table
YearSpending
2020$2,783,382
2021$2,194,177
2022$1,964,518
2023$1,589,638
2024$1,183,465

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 803 on PubMed

Sponsor: Eisai

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.